CMPS
HealthcareCOMPASS Pathways plc · Medical - Care Facilities · $1B
What is COMPASS Pathways plc?
COMPASS Pathways is a clinical-stage mental health company focused on developing psilocybin-based therapies. Operating primarily in the United Kingdom and the United States, it is working to bring novel treatments to patients with conditions that have not responded to conventional care.
The company's central program is COMP360, a proprietary psilocybin therapy developed for treatment-resistant depression, which has completed Phase IIb clinical trials. COMP360 is also being evaluated in Phase II trials for post-traumatic stress disorder. As a clinical-stage company, COMPASS does not yet generate product revenue — its business model depends on advancing its pipeline through regulatory milestones and securing future commercialization partnerships or approvals.
COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, United Kingdom.
- COMP360 psilocybin therapy for treatment-resistant depression
- Phase II PTSD clinical program using COMP360
- Proprietary psilocybin synthesis and formulation research
- Therapist training and therapy delivery model development
Is CMPS a Good Stock to Buy?
UQS Score rates CMPS as Poor overall, reflecting the early-stage nature of the business across multiple dimensions.
Among the five pillars, Risk is the least concerning — the company carries a Neutral risk profile relative to other clinical-stage peers, which may reflect its cash runway and absence of significant debt obligations typical of pre-revenue biotechs.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial revenue, an unproven competitive position, and a long path to potential product approval. Valuation is rated Elevated, suggesting the market has already priced in considerable optimism.
Sign up to view the full pillar breakdown and detailed financial metrics behind the CMPS UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CMPS pay dividends?
No — COMPASS Pathways plc does not currently pay a dividend.
COMPASS Pathways does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials, regulatory activities, and pipeline development. Income-focused investors should be aware that dividend distributions are unlikely until the company reaches commercial-stage operations.
When does CMPS report earnings?
COMPASS Pathways reports financial results on a quarterly cadence, consistent with its listing as a US-traded equity.
As a pre-revenue company, quarterly reports focus primarily on cash position, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline updates and trial readouts tend to be the most market-moving disclosures.
For the most recent quarter's results and upcoming reporting dates, visit COMPASS Pathways' investor relations page directly.
CMPS Price History
-73.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in COMPASS Pathways plc?
Based on COMPASS Pathways plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CMPS Long-term Outlook
The fundamental outlook for COMPASS Pathways is shaped almost entirely by clinical and regulatory outcomes. With Growth and Quality both rated Weak, the near-term trajectory depends on whether COMP360 can advance through later-stage trials and attract partnership or approval interest. The Elevated Valuation rating suggests the current price already reflects a degree of pipeline success that has not yet been demonstrated. The Neutral Risk rating offers some reassurance that the company is not in immediate financial distress, but the path to value creation remains long and uncertain.
Growth drivers
- Potential Phase III advancement of COMP360 for treatment-resistant depression
- Expanding PTSD trial data that could broaden the addressable patient population
- Growing regulatory and clinical interest in psychedelic-assisted therapies globally
Key risks
- Clinical trial failure or inconclusive results could significantly impair the pipeline
- Elevated valuation leaves limited margin of safety if milestones are delayed
- Pre-revenue status means continued cash burn and potential future dilution
CMPS vs Peers
COMPASS Pathways operates in the broader healthcare space alongside companies addressing different aspects of mental health and care delivery.
Sonida focuses on senior living and residential care services, operating in a completely different segment of healthcare from clinical-stage drug development.
Enhabit provides home health and hospice services, representing an established, revenue-generating care delivery model distinct from COMPASS's trial-stage approach.
AMN Healthcare is a workforce solutions company serving hospitals and health systems, operating with a commercial revenue base that contrasts with COMPASS's pre-revenue pipeline model.
Frequently Asked Questions
What does COMPASS Pathways do?
COMPASS Pathways is a clinical-stage mental health company developing COMP360, a psilocybin therapy targeting treatment-resistant depression and PTSD. The company has completed Phase IIb trials for depression and is running Phase II trials for PTSD. It does not yet have an approved or commercialized product.
Does CMPS pay dividends?
CMPS does not pay a dividend. As a pre-revenue clinical-stage company, COMPASS Pathways reinvests all available capital into its clinical programs and operations. Dividend payments are not expected until the company reaches a commercial stage, which remains contingent on regulatory outcomes.
When does CMPS report earnings?
COMPASS Pathways reports on a quarterly cadence. Because it is pre-revenue, reports center on cash runway and trial updates rather than traditional earnings metrics. Check the company's investor relations page for the most current reporting schedule.
Is CMPS a good stock to buy?
UQS Score rates CMPS as Poor, driven by Weak ratings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. This profile reflects the high uncertainty inherent in clinical-stage biotech investing. Investors should weigh pipeline risk carefully. The full pillar breakdown is available to Pro members.
Is CMPS overvalued?
The UQS Valuation pillar for CMPS is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about pipeline success. For a company with no commercial revenue, valuation is driven almost entirely by clinical trial expectations rather than current fundamentals.
How does CMPS compare to its competitors?
The companies listed alongside CMPS — Sonida Senior Living, Enhabit, and AMN Healthcare — operate in different healthcare segments with established revenue streams. COMPASS is a clinical-stage drug developer, which means its risk profile and business model differ substantially from these care-delivery and workforce peers.
What is CMPS's market cap bracket?
COMPASS Pathways is classified as a small-cap company. This is typical for clinical-stage biopharmaceutical firms whose market value is driven primarily by pipeline potential rather than existing revenue or earnings.
Who founded COMPASS Pathways?
COMPASS Pathways was founded by George Goldsmith and Ekaterina Malievskaia, who established the company with a focus on developing regulated psilocybin therapy for mental health conditions. The company was incorporated in 2020 and is headquartered in London.
Is CMPS a long-term quality investment?
As a long-term quality indicator, the UQS Score rates CMPS as Poor. Weak Quality, Moat, and Growth pillars reflect the absence of durable competitive advantages and revenue generation at this stage. Long-term quality potential depends heavily on clinical outcomes that remain unproven. Pro members can view the complete analysis.
What is the main competitive advantage of COMPASS Pathways?
COMPASS holds proprietary intellectual property around its COMP360 psilocybin formulation and has invested in a structured therapy delivery model. However, the UQS Moat pillar is rated Weak, indicating that a durable competitive advantage has not yet been established at this stage of development.
What sector does CMPS belong to?
CMPS operates in the Healthcare sector, specifically within the clinical-stage biopharmaceutical space. Its focus on psychedelic-assisted therapy places it in an emerging subsegment of mental health treatment that is attracting growing scientific and regulatory attention.
Is CMPS a growth stock or value stock?
Based on UQS pillar labels, CMPS does not fit neatly into either category. The Growth pillar is rated Weak given the pre-revenue stage, while Valuation is Elevated — meaning investors are paying a premium without current fundamental support. It is best characterized as a speculative pipeline-stage holding.
Unlock Full CMPS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for CMPS
- ✓Access detailed financial metrics and trend data
- ✓Compare CMPS against sector peers side by side
- ✓See the complete Quality and Moat breakdown
- ✓Track valuation changes over time with Pro tools
- ✓Get the full analyst-style view in one dashboard
Pro Analysis
CMPS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 15.2 | 20.0 | 11.0 | 0.0 | 49.7 | 0.0 | — |
CMPS — Pillar Breakdown
Quality
— 20.0/100 (25%)COMPASS Pathways plc currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)COMPASS Pathways plc faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 49.7/100 (15%)COMPASS Pathways plc has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)COMPASS Pathways plc appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)COMPASS Pathways plc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CMPS.
Score Composition
Financial Data
More Stock Analysis
How is the CMPS UQS Score Calculated?
The UQS (Unified Quality Score) for COMPASS Pathways plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses COMPASS Pathways plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether COMPASS Pathways plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.